Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:THRX Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Theseus Pharmaceuticals Stock (NASDAQ:THRX) 30 days 90 days 365 days Advanced Chart Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get THRX alerts:Sign Up Key Stats Today's Range$4.06▼$4.0650-Day Range$4.06▼$4.0752-Week Range$2.05▼$12.37VolumeN/AAverage Volume592,167 shsMarket Capitalization$179.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTheseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.Read More… Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive THRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address THRX Stock News HeadlinesThe True Cost of LayoffsAugust 9, 2024 | bloomberg.comKS2 / KS3 English: A Midsummer Night's Dream. 1: Welcome to AthensMay 20, 2024 | bbc.co.ukThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 23, 2024 | WealthPress (Ad)Theseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | finance.yahoo.comTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | prnewswire.comConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsJanuary 30, 2024 | finance.yahoo.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVRJanuary 20, 2024 | stockhouse.comTHESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 31, 2023 | businesswire.comSee More Headlines THRX Stock Analysis - Frequently Asked Questions How were Theseus Pharmaceuticals' earnings last quarter? Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) posted its earnings results on Monday, November, 15th. The company reported ($5.16) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $4.93. When did Theseus Pharmaceuticals IPO? Theseus Pharmaceuticals (THRX) raised $150 million in an initial public offering on Thursday, October 7th 2021. The company issued 10,000,200 shares at a price of $14.00-$16.00 per share. What other stocks do shareholders of Theseus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theseus Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings11/15/2021Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:THRX CUSIPN/A CIK1745020 Webtheseusrx.com Phone857-400-9491FaxN/AEmployees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.84% Return on Assets-23.64% Debt Debt-to-Equity RatioN/A Current Ratio29.93 Quick Ratio29.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.76Miscellaneous Outstanding Shares44,230,000Free Float23,575,000Market Cap$179.57 million OptionableOptionable Beta3.98 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:THRX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theseus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theseus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
